Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes

Biotechnology and Bioengineering

Volumn 103, Issue 6, 2009, Pages 1129-1143

  Williams, James A ^a   Luke, Jeremy ^a   Langtry, Sarah ^a   Anderson, Sheryl ^a   Hodgson, Clague P ^a   Carnes, Aaron E ^a  

^a NATURE TECHNOLOGY CORPORATION   (United States)

Author keywords

DNA vaccine; Escherichia coli; Fermentation; Gene therapy; Plasmid; Vector

Indexed keywords

ANTIGEN GENES; CELL BANKS; DNA VACCINE; DRY CELLS; FED-BATCH FERMENTATION; FERMENTATION PROCESS; GENE THERAPY; PLASMID; PLASMID DNA; PURIFICATION PROCESS;

ANTIGENS; CELL MEMBRANES; DNA; DRILLING PLATFORMS; ESCHERICHIA COLI; GENES; GENETIC ENGINEERING; METABOLISM; NUCLEIC ACIDS; PROCESS CONTROL; PRODUCTION PLATFORMS; TOXIC MATERIALS; VACCINES; VECTORS;

FERMENTATION;

ESCHERICHIA COLI PROTEIN; GWIZ PLASMID VECTOR; PLASMID DNA; PLASMID VECTOR; PROTEIN PRIA; PROTEIN PRIB; PROTEIN PRIC; PVAX1 PLASMID VECTOR; RIBOSE 5 PHOSPHATE; RIBOSE 5 PHOSPHATE ISOMERASE A; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ARTICLE; CELL LINE; CELL STRESS; CONTROLLED STUDY; FED BATCH FERMENTATION; NONHUMAN; PROTEIN EXPRESSION;

BIOTECHNOLOGY; DNA, BACTERIAL; ESCHERICHIA COLI; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; PLASMIDS; RECOMBINANT PROTEINS; VACCINES, DNA;

ESCHERICHIA COLI;

EID: 67650036224     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22347     Document Type: Article

References (43)

1. Berges H, Oreglia J, Joseph-Lianuzun E, Fayet O. 1997. Isolation and characterization of a priB mutant of Escherichia coli influencing plasmid copy number of Δrop ColE1-type plasmids. J Bacteriol 179:956-958. (Pubitemid 27051855)
2. Carnes AE. 2005. Fermentation design for the manufacture of therapeutic plasmid DNA. BioProcess Intl 3:36-44.
3. Carnes AE, Williams JA. 2007. Plasmid DNA manufacturing technology. Recent Pat Biotechnol 1:151-166.
4. Carnes AE, Hodgson CP, Williams JA. 2006. Inducible Escherichia coli fermentation for increased plasmid DNA production. Biotechnol Appl Biochem 45:155-166. (Pubitemid 44690220)
5. Cooke JR, McKie EA, Ward JM, Keshavarz-Moore E. 2004. Impact of intrinsic DNA structure on processing of plasmids for gene therapy and DNA vaccines. J Biotechnol 114:239-254. (Pubitemid 39446833)
6. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 97:6640-6645.
7. Diaz-Orejas R, Lurz R, Ruckert B. 1997. Enhancement of ColE1-type replication promoted by the GPa initiator protein of bacteriophage P4. FEMS Microbiol Lett 155:11-15. (Pubitemid 28020283)
8. Flores S, Anda-Herrera R, Gosset G, Bolivar FG. 2004. Growth-rate recovery of Escherichia coli cultures carrying a multicopy plasmid, by engineering of the pentose-phosphate pathway. Biotechnol Bioeng 87:485-494. (Pubitemid 39150050)
9. Glick BR. 1995. Metabolic load and heterologous gene expression. Biotechnol Adv 13:247-261.
10. Guzman EC, Guarino E, Riola J, Caballero JL, Jimenez-Sanchez A. 2003. Ribonucleotide diphosphate reductase is a functional and structural component of the replication hyperstructure in Escherichia coli. Recent Res Dev Mol Biol 1:29-43.
11. Haldimann A, Wanner BL. 2001. Conditional-replication, integration, excision, and retrieval plasmid-host systems for gene structure-function studies of bacteria. J Bacteriol 183:6384-6393. (Pubitemid 34059412)
12. Harinarayanan R, Gowrishankar J. 2003. Host factor titration by chromosomal R-loops as a mechanism for runaway plasmid replication in transcription termination-defective mutants of Escherichia coli. J Mol Biol 332:31-46. (Pubitemid 36999729)
13. Hoare M, Levy S, Bracewell DG, Doig SD, Kong S, Titchener-Hooker N, Ward JM, Dunnill P. 2005. Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic. Biotechnol Prog 21:1577-1592. (Pubitemid 41778980)
14. Kutzler MA, Weiner DB. 2008. DNA vaccines: Ready for prime time? Nat Rev Genet 9:776-788.
15. Lahijani R, Hulley G, Soriano G, Horn NA, Marquet M. 1996. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum Gene Ther 7:1971-1980. (Pubitemid 26390236)
16. Lee J, Him HC, Kim SW, Hong SI, Park YH. 2002. Interplay of SOS induction, recombinant gene expression, and multimerization of plasmid vectors in Escherichia coli. Biotechnol Bioeng 80:84-92.
17. Listner K, Bentley L, Okonkowski J, Kistler C, Wnek R, Caparoni A, Junker B, Robinson D, Salmon P, Chartrain M. 2006. Development of a highly productive and scalable plasmid DNA production platform. Biotechnol Prog 22:1335-1345. (Pubitemid 44568809)
18. Love CA, Lilley PE, Dixon NE. 1996. Stable high-copy-number bacteriophage lambda promoter vectors for overproduction of proteins in Escherichia coli Gene. 176:49-53.
19. Lunn CA, Kathju S, Wallace BJ, Kushner SR, Pigiet V. 1984. Amplification and purification of plasmid-encoded thioredoxin from Escherichia coli K12. J Biol Chem 259:10469-10474. (Pubitemid 14065356)
20. Marians KJ, Soeller W, Zipursky SL. 1982. Maximal limits of the Escherichia coli replication factor Y effector site sequences in pBR322 DNA. J Biol Chem 257:5656-5662. (Pubitemid 12015929)
21. Masai H, Arai KI. 1989. Escherichia coli dnaT gene function is required for pBR322 plasmid replication but not for R1 plasmid replication. J Bacteriol 171:2975-2980. (Pubitemid 19145641)
22. Masai H, Arai K. 1996. Mechanisms of primer RNA synthesis and D-loop/R-loop-dependent DNA replication in Escherichia coli. Biochimie 78:1109-1117. (Pubitemid 27193134)
23. Masse E, Drolet M. 1999. Escherichia coli DNA topoisomerase I inhibits R-loop formation by relaxing transcription-induced negative supercoiling. J Biol Chem 274:16659-16664. (Pubitemid 129526428)
24. McGlynn P, Guy CP. 2008. Replication forks blocked by protein-DNA complexes have limited stability in vitro. J Mol Biol 381:249-255.
25. Merkin EV, Mirkin SM. 2007. Replication fork stalling at natural impediments. Microbiol Mol Biol Rev 71:13-35.
26. Minden JS, Marians KJ. 1985. Replication of pBR322 DNA in vitro with purified proteins: Requirement for topoisomerase I in the maintenance of template specificity. J Biol Chem 260:9316-9325.
27. Miranda-Vizuete A, Rodriguez-Ariza A, Toribio F, Holmgren A, Lopez-Barea J, Pueyo C. 1996. The levels of ribonucleotide reductase, Thioredoxin, glutaredoxin 1, and GSH are balanced in Escherichia coli K12. J Biol Chem 271:19099-19103. (Pubitemid 26271569)
28. O'Kennedy RD, Baldwin C, Keshavarz-Moore E. 2000. Effects of growth medium selection on plasmid DNA production and initial processing steps. J Biotechnol 76:175-183.
29. O'Kennedy RD, Ward JM, Keshavarz-Moore E. 2003. Effects of fermentation strategy on the characteristics of plasmid DNA production. Biotechnol Appl Biochem 37:83-90. (Pubitemid 36246349)
30. Parada CA, Marians KJ. 1991. Mechanism of DNA A protein-dependent pBR322 DNA replication. J Biol Chem 266:18895-18906.
31. Phue JN, Lee SJ, Trinh L, Shiloach J. 2008. Modified Escherichia coli B (BL21), a superior producer of plasmid DNA compared with Escherichia coli K (DH5α). Biotechnol Bioeng 101:831-836.
32. Prather KJ, Sagar S, Murphy J, Chartrain M. 2003. Industrial scale production of plasmid DNA for vaccine and gene therapy: Plasmid design, production and purification. Enzyme Microb Technol 33:865-883. (Pubitemid 37412544)
33. Prather KJ, Edmonds MC, Herod JW. 2006. Identification and characterization of IS1 transposition in plasmid amplification mutants of E. coli clones producing DNA vaccines. Appl Microbiol Biotechnol 73:815-826.
34. Ribeiro SC, Oliveira PH, Prazeres DM, Monteiro GA. 2008. High frequency plasmid recombination mediated by 28 bp direct repeats. Mol Biotechnol 40:252-260.
35. Ricci JCD, Hernandez ME. 2000. Plasmid effects on Escherichia coli metabolism. Crit Rev Biotechnol 20:79-108.
36. Rozkov A, Avignone-Rossa CA, Ertl PF, Jones P, O'Kennedy RD, Smith J, Dale JW, Bushell ME. 2004. Characterization of the metabolic burden on Escherichia coli DH1 cells imposed by the presence of a plasmid containing a gene therapy sequence. Biotechnol Bioeng 88:909-915. (Pubitemid 39664616)
37. Sandler SJ. 2005. Requirements for replication restart proteins during constitutive stable DNA replication in Escherichia coli K-12. Genetics 169:1799-1806.
38. Schaeffer PM, Headlam MJ, Dixon NE. 2005. Protein-protein interactions in the eubacterial replisome. IUBMB Life 57:5-12.
39. Singer A, Eiteman MA, Altman E. 2009.DNA plasmid production in different host strains of Escherichia coli. J Ind Microbiol Biotechnol. 36:521-530.
40. Wang Z, Xiang L, Shao J, Wegrzyn A, Wegrzyn G. 2006. Effects of the presence of ColE1 plasmid DNA in Escherichia coli on the host cell metabolism. Microb Cell Fact 5:34. (Pubitemid 44873557)
41. Williams JA, Luke J, Johnson L, Hodgson C. 2006. pDNAVACCultra vector family: High throughput intracellular targeting DNA vaccine plasmids. Vaccine 24:4671-4676. (Pubitemid 43776763)
42. Williams JA, Carnes AE, Hodgson CP. 2009. Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production. Biotechnol Adv [Epub ahead of print].
43. Yau SY, Keshavarz-Moore E, Ward J. 2008. Host strain influences on supercoiled plasmid DNA production in Escherichia coli: Implications for efficient design of large-scale processes. Biotechnol Bioeng 101:529-544.